Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Hematology
Search Medical Condition
Hematological Disorders Clinical Trials
A listing of Hematological Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (301) clinical trials
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
The purpose of this study is to evaluate the safety and tolerability of INCB050465 when combined with bendamustine and obinutuzumab in relapsed or refractory follicular lymphoma (FL).
Aneurysm
The PulseRider® Aneurysm Neck Reconstruction Device (ANRD) is a self-expanding nitinol implant designed to retain embolic coils at a vessel bifurcation. PulseRider® is comprised of the torque device, delivery wire, introducer, and implant. (Figure 1). The implant is provided attached to the delivery wire. The PulseRider system is intended to ...
A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kd Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma
The purpose of this study is to compare INCB050465 with idelalisib for objective response rate (ORR) in subjects with relapsed or refractory follicular lymphoma (FL).
A Option for Patients with Hypertension: The RADIANCE-HTN clinical trial is a randomized, controlled study to provide additional information about the ability of the Paradise® Renal Denervation System to treat high blood pressure.
If you’ve been unable to control your blood pressure, or are interested in an alternative to daily medications, you may be a candidate for the RADIANCE-HTN Clinical Study. The investigational study is evaluating a minimally-invasive, catheter-based procedure (the Paradise® Renal Denervation System) which may lower your blood pressure and reduce ...
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
The ATR(ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas. The purpose of the proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the maximum tolerated dose of BAY1895344 that could be safely given ...
BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)
To determine the maximum tolerated and / or recommended Phase II dose of oral mutant IDH1 (mIDH1) inhibitor BAY1436032 and to characterize its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy in patients with mIDH1-R132X advanced acute myeloid leukemia (AML)
Effect of Hepatic and Renal Impairment on the Pharmacokinetics Safety and Tolerability of BAY1841788 (ODM-201)
Evaluate the potential effect of hepatic or renal impairment on the pharmacokinetics, safety and tolerability of BAY 1841788 (ODM-201).
Phase I Trial of BAY1251152 for Advanced Blood Cancers
The purpose of this study is to identify the most appropriate dose that can be safely administered and that can have an effect on blood cancer cells. Once that safe dose is identified, additional patients will be asked to join the study to further evaluate the safety and effectiveness of ...
Phase I Dose Escalation Study for BAY 1251152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of BAY 1251152 in patients with solid tumors and aggressive non-hodgkin's lymphoma (NHL).
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Patients should be in need of and fit for immunochemotherapy and should not be resistant to rituximab (resistance defined as lack of response, or progression within 6 months of the last course of treatment with a rituximab containing regimen). This study will be composed of two parts: Safety run-in and ...
